We analyzed four fragile site genes that are deleted at relatively high frequency across all cancer types: A2BP1 (7%), PARK2 (5%), WWOX (7%), and MACROD2 (6%), of which the first three have documented functional evidence of tumor suppressor activity20, 21, 22, 23. This evidence concerns the gene RBFOX1 and cancer.